Literature DB >> 19907922

p53 Regulates LIF expression in human medulloblastoma cells.

Euan W Baxter1, Jo Milner.   

Abstract

Medulloblastomas are highly malignant, poorly differentiated childhood tumours arising in the cerebellum. These tumors rarely lose TP53, which is the most commonly mutated gene in cancer. Recent work has shown that the basal level of p53 plays an important role in maternal reproduction by maintaining the expression of LIF in the uterus. Since LIF can maintain the undifferentiated state of stem cells we set out to ask if p53 regulates LIF in the human medulloblastoma cell lines DAOY and D283MED. We also used p53-/- and p53+/+ isogenic HCT116 colorectal carcinoma cell lines, already reported to exhibit p53-dependent expression of the LIF D transcript, to establish the extent of p53-dependency for LIF M and T alternative transcripts. Whilst all three known, full-length alternative transcripts are more abundant in p53+/+ cells, the alternative LIF M and T transcripts appear particularly sensitive to p53. In the p53 wild-type medulloblastoma cell line D283MED chromatin immunoprecipitation experiments showed p53 binding to the LIF gene. The mutant p53 expressed in line DAOY did not bind to this region or to the p21(WAF1) p53 binding site. RNA interference against either WIP1 or SIRT1 stabilized p53 and enhanced the transcription of LIF in D283MED cells. Interestingly, siRNA against WIP1 or SIRT1 also induced increased apoptosis in the medulloblastoma line D283MED and, over a longer time period, in DAOY cells. We speculate that suppression of p53 function by combined WIP1-mediated dephosphorylation and SIRT1 deacetylation enables medulloblastoma cell survival but p53-dependent and independent apoptotic pathways remain intact. Thus small molecule inhibitors of SIRT1 may be useful in treatment of medulloblastoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19907922     DOI: 10.1007/s11060-009-0043-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  Intracellular and extracellular leukemia inhibitory factor proteins have different cellular activities that are mediated by distinct protein motifs.

Authors:  B P Haines; R B Voyle; P D Rathjen
Journal:  Mol Biol Cell       Date:  2000-04       Impact factor: 4.138

2.  Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex.

Authors:  Qinghong Zhang; Su-Yan Wang; Capucine Fleuriel; Dominique Leprince; Jonathan V Rocheleau; David W Piston; Richard H Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-09       Impact factor: 11.205

3.  Differentiation inhibiting activity is produced in matrix-associated and diffusible forms that are generated by alternate promoter usage.

Authors:  P D Rathjen; S Toth; A Willis; J K Heath; A G Smith
Journal:  Cell       Date:  1990-09-21       Impact factor: 41.582

4.  Complex conserved organization of the mammalian leukemia inhibitory factor gene: regulated expression of intracellular and extracellular cytokines.

Authors:  B P Haines; R B Voyle; T A Pelton; R Forrest; P D Rathjen
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

5.  Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.

Authors:  Emma Langley; Mark Pearson; Mario Faretta; Uta-Maria Bauer; Roy A Frye; Saverio Minucci; Pier Giuseppe Pelicci; Tony Kouzarides
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

6.  Negative control of p53 by Sir2alpha promotes cell survival under stress.

Authors:  J Luo; A Y Nikolaev; S Imai; D Chen; F Su; A Shiloh; L Guarente; W Gu
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

7.  Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.

Authors:  H Fujimoto; N Onishi; N Kato; M Takekawa; X Z Xu; A Kosugi; T Kondo; M Imamura; I Oishi; A Yoda; Y Minami
Journal:  Cell Death Differ       Date:  2005-11-25       Impact factor: 15.828

8.  Expression of leukemia-inhibitory factor as an autocrinal growth factor in human medulloblastomas.

Authors:  J Liu; J W Li; Y Gang; L Guo; H Li
Journal:  J Cancer Res Clin Oncol       Date:  1999 Aug-Sep       Impact factor: 4.553

9.  Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.

Authors:  Janet C Lindsey; Meryl E Lusher; Jennifer A Anderton; Simon Bailey; Richard J Gilbertson; Andrew D J Pearson; David W Ellison; Steven C Clifford
Journal:  Carcinogenesis       Date:  2003-12-19       Impact factor: 4.944

10.  p53 regulates maternal reproduction through LIF.

Authors:  Wenwei Hu; Zhaohui Feng; Angelika K Teresky; Arnold J Levine
Journal:  Nature       Date:  2007-11-29       Impact factor: 49.962

View more
  14 in total

1.  Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma.

Authors:  G G Sun; J Zhang; X B Ma; Y D Wang; Y J Cheng; W N Hu
Journal:  Pathol Oncol Res       Date:  2014-07-25       Impact factor: 3.201

2.  HDM2 promotes WIP1-mediated medulloblastoma growth.

Authors:  Meghan C Buss; Tracy-Ann Read; Matthew J Schniederjan; Khanjan Gandhi; Robert C Castellino
Journal:  Neuro Oncol       Date:  2012-02-29       Impact factor: 12.300

3.  WIP1 enhances tumor formation in a sonic hedgehog-dependent model of medulloblastoma.

Authors:  Tiffany A Doucette; Yuhui Yang; Carolyn Pedone; John Y H Kim; Adrian Dubuc; Paul D Northcott; Michael D Taylor; Daniel W Fults; Ganesh Rao
Journal:  Neurosurgery       Date:  2012-04       Impact factor: 4.654

4.  Wip1 gene silencing enhances the chemosensitivity of human colon cancer cells.

Authors:  Zhong-Sheng Xia; Di Wu; Wa Zhong; Xi-Ji Lu; Tao Yu; Qi-Kui Chen
Journal:  Oncol Lett       Date:  2017-06-09       Impact factor: 2.967

5.  The transcription factor Cux1 in cerebellar granule cell development and medulloblastoma pathogenesis.

Authors:  Sabine Topka; Alexander Glassmann; Gunnar Weisheit; Ulrich Schüller; Karl Schilling
Journal:  Cerebellum       Date:  2014-12       Impact factor: 3.847

Review 6.  Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.

Authors:  Bryant England; Tiangui Huang; Michael Karsy
Journal:  Tumour Biol       Date:  2013-06-05

7.  Expression of Wip1 in kidney carcinoma and its correlation with tumor metastasis and clinical significance.

Authors:  G G Sun; Y D Wang; Q Liu; W N Hu
Journal:  Pathol Oncol Res       Date:  2014-06-28       Impact factor: 3.201

8.  Proto-oncogene Wip1, a member of a new family of proliferative genes in NSCLC and its clinical significance.

Authors:  Zhanzhao Fu; Guogui Sun; Tao Gu
Journal:  Tumour Biol       Date:  2013-11-23

Review 9.  The emerging role of leukemia inhibitory factor in cancer and therapy.

Authors:  Cen Zhang; Juan Liu; Jianming Wang; Wenwei Hu; Zhaohui Feng
Journal:  Pharmacol Ther       Date:  2020-11-28       Impact factor: 12.310

10.  The role of PPM1D in cancer and advances in studies of its inhibitors.

Authors:  Wenhong Deng; Jieqing Li; Kimberly Dorrah; Denise Jimenez-Tapia; Brando Arriaga; Qiongyu Hao; Wei Cao; Zhaoxia Gao; Jay Vadgama; Yong Wu
Journal:  Biomed Pharmacother       Date:  2020-01-29       Impact factor: 7.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.